MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
about
Bladder Preservation for Muscle Invasive Bladder CancerEffect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitroNBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancerDouble-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcomeRole of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancerDNA Repair Pathway Alterations in Bladder Cancer.Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer.MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells.Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to ChemoradiotherapySelective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.Biomarkers for prognosis and treatment selection in advanced bladder cancer patients.Trimodality therapy in bladder cancer: who, what, and when?The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.Biomarker development in the context of urologic cancersLow cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.Urothelial carcinoma management in elderly or unfit patients.Investigation of radiosensitivity gene signatures in cancer cell lines.Strategies for optimizing the response of cancer and normal tissues to radiation.Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM.Current management of muscle-invasive bladder cancer.Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.Gene expression profile is associated with chemoradiation resistance in rectal cancer.Predictive markers of radiotherapy-induced rectal cancer regression.Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives.Noninvasive approaches for detecting and monitoring bladder cancer.DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets.Developing proteomic biomarkers for bladder cancer: towards clinical application.Radiogenomics and radiotherapy response modeling.Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumoursComet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo.Imatinib radiosensitizes bladder cancer by targeting homologous recombination.Landmarks in the treatment of muscle-invasive bladder cancer.H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer.No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy.EXD2 - a new player joins the DSB resection team.Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply.
P2860
Q26744750-C383C97E-5D8A-4984-8512-FDC7A9715636Q27853018-EBF78F69-DFBD-497D-AB46-387EBA3DA495Q28251928-494A8DA0-797D-4293-AF0F-889E570A1084Q28271788-7E53E2EE-E6AF-45D4-84A9-C1CC95CD4C81Q28273513-2DA028D4-803C-4CCC-9071-45E4E41F55E0Q33607945-5B1A058F-E4EE-4CAD-A8B5-44137B322B70Q34004008-3925C5E0-A841-4545-A85F-F9E7542AD76AQ34500446-A71D0509-BA3A-4570-A6CA-62D3A4D7778BQ34551018-AFF8C048-CE01-40AC-A109-8A98F8BD0B21Q34670535-87F79D77-2B3C-48B3-BF2B-CCA63B8DDA96Q35495280-4256DABB-6557-4E5B-9AC5-E4E7AC6C1443Q35603639-051A02AF-24B0-4AFD-B6AA-717A578B10D0Q35671292-B2AE6942-D72C-4FDF-8B63-A842E6AD18EFQ35733590-D4C92C87-BF5A-4E15-A94E-D34DDCD31F87Q35795350-5AB54311-A136-4924-95D9-6DF2B14D631BQ35869645-7C4B58A7-9AA2-4B63-8AFC-72923B152244Q35906352-2B087A4B-FD93-43F9-8C62-9612DEBF40E8Q36511735-9CF0A41A-D4F1-40D1-84C5-B10470401E2DQ37030514-4F0344D0-6F50-4CBF-993E-B5691BA0CDB9Q37505655-77A3FB35-CE18-4687-93AA-06005439DD60Q37531724-F1BF601E-A3FC-4ECA-9FCA-B2E138E2093AQ37671964-E25BECA0-210B-4D8E-B3CC-4F63BD9A0BCFQ37705828-45A708B9-6DE0-4426-960C-D52C8339F91FQ37962658-58A62E31-F8CA-4917-9B7A-BF9D44F7AF4BQ38076093-DF64963D-CE4B-4C7F-831E-A8A18E515ABBQ38137324-8B381A28-A0FA-4E23-8F47-DA780C667FE8Q38239477-802008E1-DE0B-4ABE-AB81-1008877F60BBQ38255032-117E720C-E7C5-4336-9418-15DC5E7DCC7AQ38286089-726611A2-ADA7-4E9D-9F01-F46FA2505E9EQ38422476-A262323A-2152-45BE-9599-C2968EA1538FQ38511509-CEC0ADA0-953F-444B-8634-0F162DF0DEA2Q38665620-BAF0CE7B-03D5-4797-8D62-E19E0B205917Q39015929-7A344F23-B115-4763-9DD6-5497ED98F396Q39107932-9222B632-8DBA-488E-9E2B-2F32307D97A8Q39213528-6E2AFFBD-6FE6-4633-A794-19A6B09A171EQ39413207-1B0CFA0E-751A-4DDC-9A3E-ED4774591077Q39579247-D16DD5DD-889C-49D2-A99F-439035426E90Q40161797-30624FEE-85D4-45D2-8FE9-73ADE11C257AQ42285721-2E794EB5-B062-4F11-B178-1FB9569D80B4Q43081709-C1395DFD-A9D8-4274-8D2C-2EE4EDDFCD64
P2860
MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@ast
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@en
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@en-gb
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@nl
type
label
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@ast
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@en
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@en-gb
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@nl
prefLabel
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@ast
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@en
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@en-gb
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@nl
P2093
P2860
P50
P1433
P1476
MRE11 expression is predictive ...... uscle-invasive bladder cancer.
@en
P2093
Claire F Taylor
Colin F Johnston
Faye Elliott
Johanna Lowery
Johanne Bentley
Louisa D Nelson
Mark T W Teo
Michael Churchman
Patricia Harnden
Sameer Chilka
P2860
P304
P356
10.1158/0008-5472.CAN-10-1202
P407
P577
2010-09-01T00:00:00Z